Item 6. EXHIBITS

8K characters. Original on sec.gov · Markdown

Item 6. EXHIBITS

Exhibits (listed by number corresponding to the Exhibit Table of Item 601 in Regulation S-K).


Exhibit No.						Description
3a.						Amended and Restated Certificate of Incorporation of Bristol-Myers Squibb Company, as further amended.
31a.						Section 302 Certification Letter.
31b.						Section 302 Certification Letter.
32a.						Section 906 Certification Letter.
32b.						Section 906 Certification Letter.
101.INS						XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH						XBRL Taxonomy Extension Schema Document.
101.CAL						XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF						XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB						XBRL Taxonomy Extension Label Linkbase Document.
101.PRE						XBRL Taxonomy Extension Presentation Linkbase Document.
104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Indicates, in this Quarterly Report on Form 10-Q, brand names of products, which are registered trademarks not solely owned by the Company or its subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd.; Gleevec is a trademark of Novartis AG; Keytruda is a trademark of Merck Sharp & Dohme Corp; Onglyza is a trademark of AstraZeneca AB; Otezla is a trademark of Amgen Inc.; Plavix is a trademark of Sanofi; and Tecentriq is a trademark of Genentech, Inc. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries.

SUMMARY OF ABBREVIATED TERMS

Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:


2023 Form 10-K	Annual Report on Form 10-K for the fiscal year ended December 31, 2023	Merck	Merck & Co.
2024 Senior Unsecured Notes	Aggregate principal amount of $13.0 billion of unsecured senior notes issued by BMS in February 2024	LBCL	Large B-cell Lymphoma
aGVHD	acute graft-versus-host disease	Mirati	Mirati Therapeutics, Inc.
ANDA	Abbreviated New Drug Application	MPM	malignant pleural mesothelioma
AstraZeneca	AstraZeneca PLC	MTA	Methylthioadenosine
BCMA	B-cell maturation antigen-directed	NKT	natural killer T cells
CAR-T	chimeric antigen receptor T-cell	NDA	New Drug Application
Celgene	Celgene Corporation	NSCLC	non-small cell lung cancer
CERCLA	U.S. Comprehensive Environmental Response, Compensation and Liability Act	NTRK	Neurotrophic Tropomyosin Receptor Kinase
CGDP	Coverage Gap Discount Program	Nimbus	Nimbus Therapeutics
CLL	Chronic Lymphocytic Leukemia	NVAF	non-valvular atrial fibrillation
CML	chronic myeloid leukemia	OECD	Organization for Economic Co-operation and Development
CRC	colorectal carcinoma	Ono	Ono Pharmaceutical Co., Ltd
CTLA4	Cytotoxic T-lymphocyte Antigen-4	Otsuka	Otsuka Pharmaceutical Co., Ltd.
DLBCL	Diffuse Large B-cell Lymphoma	PD-1	programmed cell death protein 1
EC	European Commission	PDUFA	Prescription Drug User Fee Act
Eisai	Eisai Co., Ltd.	PsA	psoriatic arthritis
EPS	earnings per share	PRMT5	protein arginine methyltransferase 5
EU	European Union	Quarterly Report on Form 10-Q	Quarterly Report on Form 10-Q for the quarter ended June 30, 2024
Exchange Act	the Securities Exchange Act of 1934	R&D	research and development
FASB	Financial Accounting Standards Board	RA	rheumatoid arthritis
FDA	U.S. Food and Drug Administration	RayzeBio	RayzeBio, Inc.
FL	follicular lymphoma	RCC	renal cell carcinoma
GAAP	generally accepted accounting principles	REMS	risk evaluation and mitigation strategy
GTN	gross-to-net	Sanofi	Sanofi S.A.
HCC	hepatocellular carcinoma	SEC	U.S. Securities and Exchange Commission
HCM	hypertrophic cardiomyopathy	SLL	Small Lymphocytic Lymphoma
IPRD	in-process research and development	SPC	Supplementary Protection Certificate
IRA	Inflation Reduction Act of 2022	SystImmune	SystImmune, Inc.
IRS	Internal Revenue Service	Takeda	Takeda Pharmaceutical Company Limited
IV	intravenous	TCJA	Tax Cuts and Jobs Act
JIA	juvenile idiopathic arthritis	Turning Point	Turning Point Therapeutics, Inc.
Juno	Juno Therapeutics, Inc.	UC	ulcerative colitis
Karuna	Karuna Therapeutics, Inc.	UK	United Kingdom
KRAS	Kirsten rat sarcoma	U.S.	United States
MDL	multi-district litigation	USPTO	U.S. Patent and Trademark Office
MDS	myelodysplastic syndromes	VAT	value added tax

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		BRISTOL-MYERS SQUIBB COMPANY (REGISTRANT)

Date:	July 26, 2024	By:	/s/ Christopher Boerner, Ph.D.
			Christopher Boerner, Ph. D. Chair of the Board and Chief Executive Officer

Date:	July 26, 2024	By:	/s/ David V. Elkins
			David V. Elkins Chief Financial Officer

Previous: Item 5. OTHER INFORMATION